Tech Review

Future challenges in biomanufacturing

22.08.2011

Outsourcing is one of the biggest global trends in the biopharmaceutical industry. It is taking more and more specific know-how to master the challenges posed by manufacturing of biologics, which include rising price and cost pressures, the need for high flexibility, and the ever-shifting (and in most cases

growing) regulatory requirements for biomanufacturing. This article will give you an overview of how a contract manufacturing organisation (CMO) with many years of experience in manufacturing several classes of bio­pharmaceuticals is positioning itself to face these challenges.

In the maturing biopharmaceutical industry today, there is increasing competition to innovative pipelines from me-too products, biobetters and biosimilars. The pressure on the cost of goods (COG) is therefore increasing. And to reduce COG, each manufacturing facility needs to meet the specific requirements for a new project regarding the technical instrumentation even before the project enters its initial stages. This will reduce investment and later depreciation, which impact negatively on costs. At the same time, it is important to be able to maintain as much flexibility as possible in order to comply with upcoming regulatory requirements. Thus CMOs need to invest constantly in the development and establishment of new manufacturing technologies and the necessary equipment.

Implementation of new

process technologies

At Richter-Helm, the investment in new technology does not focus only on adding new (greater) manufacturing scales, although this is often a first reaction to COG pressure. Many firms consider

decreasing costs by increasing scale.
But a good alternative to simple scale-up is the implementation of new process technologies that can achieve higher yields, while at the same time improving quality or process robustness – at least for certain processing steps. Over the past few years, the biomanufacturing industry has made substantial improvements in expression and fermentation technologies. In terms of microbial production, innovative E. coli expression systems combined with high density fermentation regimes can lead to yields up to 20g of the target protein per litre of fermentation broth – as was recently accomplished by Richter-Helm for a fusion protein process[1].
In addition to high product yields, in many cases it is also important to find the appropriate expression system for high-quality products that show no or only low expression rates in E. coli. In these cases, the use of other bacterial expression hosts such as Bacillus or Pseudomonas strains can help. Pichia pastoris technology is another option for dealing with even more complex proteins such as enzymes or antibody fragments. A multipurpose facility for manufacturing bio­pharmaceuticals therefore needs to be equipped to take advantage of all these expression systems in order to be able to reduce upfront investment costs from the outset.
New expression systems lead to high primary product yields, and these need to be dealt with in purification processes. Thus optimisation of the downstream processes is also necessary. A recent study showed that the implementation of EBA technology can reduce total process cost by up to 56%[2]. Other new purification technologies that can be implemented include multi­column counter current solvent gradient purification (MCSGP), which reduces the loss of product in chromatography steps.
An ongoing trend in biopharmaceutical product development is the covalent modification of proteins by chemical or enzymatic cross linking (e.g. PEGylation, HESylation, Polyasialation) to increase the half-life of those products in humans. These technologies therefore need to be accessible in a multipurpose facility as well.

Expert project management

Of course, all of the technologies mentioned above also need to be scalable. For a CMO to offer customers the option of going from bench to market with a single manufacturer, it is important to offer more than one scale. For instance, at Richter-Helm three different manufacturing scales are available (lab, pilot, large) to implement each project at the best matching scale while limiting costs for large equipment or a higher number of batches (Fig. 1).
But a CMO does not only need sufficient technical capabilities to serve the future needs of its customers. Professional project execution is also a major success factor. It is extremely important for a CMO to be prepared for the fact that different customers have different requirements, as they range from small start-ups to big pharma. The project approach, for example regarding the regulatory consultancy required, will be extremely dependent on the customer’s situation (Fig. 2). Project management that ensures close collaboration and communication between all parties is becoming increasingly important, driven by the trend towards long-lasting partnerships and strategic alliances between developers and manufacturers.D


References
[1] Kaiser et al., Steigerung von Qualität und Ausbeute in der Wirkstoffproduktion; Laborwelt 11 (3), 18-22, 2010
[2] May, Pohlmeyer; Improving Process Economy with Expanded-Bed Adsorption Technology, BioProcess International, January 2011

Contact
Dr. Kai Pohlmeyer
Dr.-Ing. Philipp Göpel
Richter-Helm BioTec GmbH & Co. KG
Nordkanalstrasse 28
20097 Hamburg, Germany
Tel.: +49 40 2375-0
k.pohlmeyer@richter-helm-biotec.eu
p.goepel@richter-helm-biotec.eu
www.richter-helm-biotec.eu

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1982

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/future-challenges-in-biomanufacturing.html

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • THERAMETRICS (CH)0.09 CHF12.50%
  • AB SCIENCE (F)11.21 EUR9.37%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.80 EUR268.4%
  • SANTHERA (CH)65.50 CHF81.9%
  • ADDEX (CH)4.01 CHF79.0%

FLOP

  • MERCK KGAA (D)65.21 EUR-48.8%
  • HYBRIGENICS (F)1.74 EUR-28.7%
  • PROSENSA (NL)9.65 USD-23.5%

TOP

  • SANTHERA (CH)65.50 CHF3175.0%
  • GW PHARMACEUTICALS (UK)412.50 GBP630.1%
  • PAION (D)2.74 EUR315.2%

FLOP

  • CYTOS (CH)0.28 CHF-91.8%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.45 EUR-69.7%

No liability assumed, Date: 28.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products